149 related articles for article (PubMed ID: 16788929)
1. Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer.
Du KL; Mick R; Busch TM; Zhu TC; Finlay JC; Yu G; Yodh AG; Malkowicz SB; Smith D; Whittington R; Stripp D; Hahn SM
Lasers Surg Med; 2006 Jun; 38(5):427-34. PubMed ID: 16788929
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic therapy in the canine prostate using motexafin lutetium.
Hsi RA; Kapatkin A; Strandberg J; Zhu T; Vulcan T; Solonenko M; Rodriguez C; Chang J; Saunders M; Mason N; Hahn S
Clin Cancer Res; 2001 Mar; 7(3):651-60. PubMed ID: 11297261
[TBL] [Abstract][Full Text] [Related]
3. Updated results of a phase I trial of motexafin lutetium-mediated interstitial photodynamic therapy in patients with locally recurrent prostate cancer.
Verigos K; Stripp DC; Mick R; Zhu TC; Whittington R; Smith D; Dimofte A; Finlay J; Busch TM; Tochner ZA; Malkowicz S; Glatstein E; Hahn SM
J Environ Pathol Toxicol Oncol; 2006; 25(1-2):373-87. PubMed ID: 16566729
[TBL] [Abstract][Full Text] [Related]
4. Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light.
Yu G; Durduran T; Zhou C; Zhu TC; Finlay JC; Busch TM; Malkowicz SB; Hahn SM; Yodh AG
Photochem Photobiol; 2006; 82(5):1279-84. PubMed ID: 16696593
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic therapy with motexafin lutetium for rectal cancer: a preclinical model in the dog.
Ross HM; Smelstoys JA; Davis GJ; Kapatkin AS; Del Piero F; Reineke E; Wang H; Zhu TC; Busch TM; Yodh AG; Hahn SM
J Surg Res; 2006 Oct; 135(2):323-30. PubMed ID: 16650871
[TBL] [Abstract][Full Text] [Related]
6. Preclinical evaluation of motexafin lutetium-mediated intraperitoneal photodynamic therapy in a canine model.
Griffin GM; Zhu T; Solonenko M; Del Piero F; Kapakin A; Busch TM; Yodh A; Polin G; Bauer T; Fraker D; Hahn SM
Clin Cancer Res; 2001 Feb; 7(2):374-81. PubMed ID: 11234893
[TBL] [Abstract][Full Text] [Related]
7. In vivo reflectance measurement of optical properties, blood oxygenation and motexafin lutetium uptake in canine large bowels, kidneys and prostates.
Solonenko M; Cheung R; Busch TM; Kachur A; Griffin GM; Vulcan T; Zhu TC; Wang HW; Hahn SM; Yodh AG
Phys Med Biol; 2002 Mar; 47(6):857-73. PubMed ID: 11936174
[TBL] [Abstract][Full Text] [Related]
8. In vivo light dosimetry for motexafin lutetium-mediated PDT of recurrent breast cancer.
Dimofte A; Zhu TC; Hahn SM; Lustig RA
Lasers Surg Med; 2002; 31(5):305-12. PubMed ID: 12430147
[TBL] [Abstract][Full Text] [Related]
9. Spatial distribution of liposome encapsulated tin etiopurpurin dichloride (SnET2) in the canine prostate: implications for computer simulation of photodynamic therapy.
Aniola J; Selman SH; Lilge L; Keck R; Jankun J
Int J Mol Med; 2003 Mar; 11(3):287-91. PubMed ID: 12579328
[TBL] [Abstract][Full Text] [Related]
10. Studies of a vascular-acting photosensitizer, Pd-bacteriopheophorbide (Tookad), in normal canine prostate and spontaneous canine prostate cancer.
Huang Z; Chen Q; Luck D; Beckers J; Wilson BC; Trncic N; Larue SM; Blanc D; Hetzel FW
Lasers Surg Med; 2005 Jun; 36(5):390-7. PubMed ID: 15856509
[TBL] [Abstract][Full Text] [Related]
11. Preclinical studies in normal canine prostate of a novel palladium-bacteriopheophorbide (WST09) photosensitizer for photodynamic therapy of prostate cancers.
Chen Q; Huang Z; Luck D; Beckers J; Brun PH; Wilson BC; Scherz A; Salomon Y; Hetzel FW
Photochem Photobiol; 2002 Oct; 76(4):438-45. PubMed ID: 12405153
[TBL] [Abstract][Full Text] [Related]
12. Lipophilic photosensitizer administration via the prostate arteries for photodynamic therapy of the canine prostate.
Xiao Z; Owen RJ; Liu W; Tulip J; Brown K; Woo T; Moore RB
Photodiagnosis Photodyn Ther; 2010 Jun; 7(2):106-14. PubMed ID: 20510305
[TBL] [Abstract][Full Text] [Related]
13. Photodynamic therapy for prostate cancer--an emerging approach for organ-confined disease.
Moore CM; Emberton M; Bown SG
Lasers Surg Med; 2011 Sep; 43(7):768-75. PubMed ID: 22057504
[TBL] [Abstract][Full Text] [Related]
14. Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy.
Zhu TC; Finlay JC; Hahn SM
J Photochem Photobiol B; 2005 Jun; 79(3):231-41. PubMed ID: 15896650
[TBL] [Abstract][Full Text] [Related]
15. Optical properties of human prostate at 732 nm measured in mediated photodynamic therapy.
Zhu TC; Dimofte A; Finlay JC; Stripp D; Busch T; Miles J; Whittington R; Malkowicz SB; Tochner Z; Glatstein E; Hahn SM
Photochem Photobiol; 2005; 81(1):96-105. PubMed ID: 15535736
[TBL] [Abstract][Full Text] [Related]
16. Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.
Patel H; Mick R; Finlay J; Zhu TC; Rickter E; Cengel KA; Malkowicz SB; Hahn SM; Busch TM
Clin Cancer Res; 2008 Aug; 14(15):4869-76. PubMed ID: 18676760
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of interstitial Doppler optical coherence tomography for in vivo detection of microvascular changes during photodynamic therapy.
Li H; Standish BA; Mariampillai A; Munce NR; Mao Y; Chiu S; Marcon NE; Wilson BC; Vitkin A; Yang VX
Lasers Surg Med; 2006 Sep; 38(8):754-61. PubMed ID: 16927368
[TBL] [Abstract][Full Text] [Related]
18. Studies of tin ethyl etiopurpurin photodynamic therapy of the canine prostate.
Selman SH; Albrecht D; Keck RW; Brennan P; Kondo S
J Urol; 2001 May; 165(5):1795-801. PubMed ID: 11342978
[TBL] [Abstract][Full Text] [Related]
19. Optical characteristics of the canine prostate at 665 nm sensitized with tin etiopurpurin dichloride: need for real-time monitoring of photodynamic therapy.
Jankun J; Lilge L; Douplik A; Keck RW; Pestka M; Szkudlarek M; Stevens PJ; Lee RJ; Selman SH
J Urol; 2004 Aug; 172(2):739-43. PubMed ID: 15247773
[TBL] [Abstract][Full Text] [Related]
20. Laser dosimetry studies in the prostate.
Chen Q; Hetzel FW
J Clin Laser Med Surg; 1998 Feb; 16(1):9-12. PubMed ID: 9728124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
